NY-ESO-1 immunotherapy for multiple myeloma (Q36637651)

15 August 2017

1 reference

title

NY-ESO-1 immunotherapy for multiple myeloma (English)

1 reference

15 August 2017

1 reference

3

Frits van Rhee

0 references

author name string

Susann Szmania

series ordinal

1

1 reference

15 August 2017

Guido Tricot

series ordinal

2

1 reference

15 August 2017

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

47

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

2037-2048

1 reference

Long-term follow-up after high-dose therapy for high-risk multiple myeloma

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cure of myeloma: hype or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 and CD8 T cell responses in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

DNA vaccines to attack cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Combined real time PCR and immunohistochemical evaluation of sperm protein 17 as a cancer-testis antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Direct activation of TERT transcription by c-MYC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Sperm protein 17 is expressed in human somatic ciliated epithelia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

LAGE-1, a new gene with tumor specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Imaging the cranial nerves in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cancer/testis-associated genes: identification, expression profile, and putative function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

NY-ESO-1 expression and immunogenicity in esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Tumour-associated antigens in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Immunotherapy in multiple myeloma--possibility or probability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Induction of primary NY-ESO-1 immunity: CD8 T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1 cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

CD4( ) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

CD8( ) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Immunodominant CD4 responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

The central role of CD4( ) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

B-cell epitopes from the cancer testis antigen NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Multiepitope CD8( ) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Getting peptide vaccines to work: just a matter of quality control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

High-Level Expression of Cancer/Testis Antigen NY-ESO-1 and Human Granulocyte-Macrophage Colony-Stimulating Factor in Dendritic Cells with a Bicistronic Retroviral Vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Shedding light on immunotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Human tumor-specific T lymphocytes: does function matter more than number?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

TGF-β: A Critical Modulator of Immune Cell Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Large-scale depletion of CD25 regulatory T cells from patient leukapheresis samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Epigenetic immunomodulation of hematopoietic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Immunomodulation of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Clinical-grade myeloma Ag pre-loaded DC vaccines retain potency after cryopreservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/10428190600742292

10.1080/10428190600742292

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yaglyhy2nfdplowrjqi5qiuxo4

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_yaglyhy2nfdplowrjqi5qiuxo4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yaglyhy2nfdplowrjqi5qiuxo4

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/yaglyhy2nfdplowrjqi5qiuxo4

1 reference